(lp0
S'Idera Pharmaceuticals Inc.  Soars 8.25% on March 20 Equities.com - 9 hours ago Idera Pharmaceuticals Inc.  had a good day on the market for Monday March 20 as shares jumped 8.25% to close at $2.23.Stock Volatility Risk Alert: Idera Pharmaceuticals Inc Price Volatility Hits ... - CML NewsThe Idera Pharmaceuticals Inc  Sees Unusually-High Trading Volume After ... - Petro Global News 24'
p1
aS'Risk Alert in Option Market: Idera Pharmaceuticals Inc Implied Price Swing ... CML News - 11 hours ago Risk Alert: Before we dive into any analysis we simply note that Idera Pharmaceuticals Inc  risk is at an extremely elevated level.'
p2
aS"How Much Potential Does Idera Pharmaceuticals' Pipeline Really Have? Motley Fool - Oct 9, 2016 However, Idera isn't the only company developing a potential treatment for the disease. Corbus Pharmaceuticals  expects to complete enrollment in the first half of 2017 for its phase 2 study of Resunab in treating dermatomyositis. Resunab&nbsp;..."
p3
aS'Why Idera Pharmaceuticals Inc Stock Is Falling Again Motley Fool - Oct 7, 2016 Investors in Idera Pharmaceuticals  are having another rough day. Shares are down by more than 10% as of 11:45 a.m.Idera Pharma  Prices 25M Common Stock Offering for Proceeds of $50M - StreetInsider.com'
p4
aS"Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially ... Seeking Alpha - Feb 27, 2017 Idera Pharmaceuticals  is a clinical-stage biopharmaceutical company developing novel nucleic acid based therapies for the treatment of certain cancers and rare diseases.Stock Movers  MannKind Corporation , Idera Pharmaceuticals Inc ... - Wall Street Times Volatility Analysis: Idera Pharmaceuticals, Inc.  - The Oracle Examiner"
p5
aS'Why Idera Pharmaceuticals Inc. Is Down Big Today Motley Fool - Oct 6, 2016 Idera produced a net loss of $26.3 million through the first half of the year, leaving it with only $64.1 million in cash as of the end of June.Idera Announces $50M Public Offering  - Investopedia'
p6
aS'Idera Pharmaceuticals: An Intriguing Biotech Buy With Near-Term Catalysts Seeking Alpha - Oct 14, 2016 The company is currently exploring strategic options with former lead treatment IMO-8400, opting instead to focus resources on its immuno-oncology candidate, IMO-2125.'
p7
aS'Idera Pharmaceuticals Inc  Reports Additional Phase 1/2 Data In ... Smarter Analyst - Feb 24, 2017 Idera Pharmaceuticals Inc  is reporting additional data from the dose-escalation phase of its ongoing Phase 1/2 clinical trial of intratumoral IMO-2125, an agonist of TLR9 in combination with ipilimumab or pembrolizumab for treatment of&nbsp;...Analyst Activity  Wedbush Reiterates Outperform on Idera Pharmaceuticals ... - Market Exclusive'
p8
aS'Stock Update : Idera Pharmaceuticals Inc Announces Appointment of ... Smarter Analyst - Feb 6, 2017 Idera Pharmaceuticals Inc  announced the appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development.Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice ... - GlobeNewswire '
p9
aS'Doubling Down On Idera Seeking Alpha - Jan 30, 2017 Management successfully created shareholder value through entering into an exclusive license for worldwide rights to IMO-9200 with Vivelix Pharmaceuticals. The company received $15 million upfront and could be in line for up to $140 million in ...'
p10
a.